

Adamas Pharmaceuticals Inc  
 Form 4  
 March 19, 2015

**FORM 4**

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
 Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0287  
 Expires: January 31, 2015  
 Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person \*  
 Went Gregory T

2. Issuer Name and Ticker or Trading Symbol  
 Adamas Pharmaceuticals Inc  
 [ADMS]

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

(Last) (First) (Middle)

3. Date of Earliest Transaction (Month/Day/Year)  
 03/17/2015

Director  10% Owner  
 Officer (give title below)  Other (specify below)  
 Chief Executive Officer

C/O ADAMAS  
 PHARMACEUTICALS, INC., 1900  
 POWELL ST., SUITE 750

(Street)

4. If Amendment, Date Original Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check Applicable Line)  
 Form filed by One Reporting Person  
 Form filed by More than One Reporting Person

EMERYVILLE, CA 94608

(City) (State) (Zip)

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

| 1. Title of Security (Instr. 3) | 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year) | 3. Transaction Code (Instr. 8) | 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Ownership (Instr. 4)                  |
|---------------------------------|--------------------------------------|--|--------------------------------|---|---|--|--|
|                                 |                                      |  | Code                           | V   | Amount  | (A) or (D)   | Price  |
| Common Stock                    | 03/17/2015                           |  | M                              |   | 1,900   | A  | \$ 1.875   |
|                                 |                                      |  |                                |   | 1,908 <sup>(1)</sup>  | D  |  |
| Common Stock                    | 03/17/2015                           |  | S                              |   | 1,900   | D  | \$ 18  |
|                                 |                                      |  |                                |   | 8 <sup>(1)</sup>  | D  |  |
| Common Stock                    | 03/17/2015                           |  | S                              |   | 2,700   | D  | \$ 18  |
|                                 |                                      |  |                                |   | 417,748   | I  |  |
|                                 |                                      |  |                                |   |   |  | Gregory T Went & Marjorie S Went ttees Went Family |

Edgar Filing: Adamas Pharmaceuticals Inc - Form 4

|              |            |   |        |   |                           |                       |   |  |
|--------------|------------|---|--------|---|---------------------------|-----------------------|---|--|
| Common Stock | 03/18/2015 | M | 4,600  | A | \$ 1.875                  | 4,608 <sup>(1)</sup>  | D | Living Trust dtd 03/24/11  |
| Common Stock | 03/18/2015 | S | 4,600  | D | \$ 18.0007 <sup>(2)</sup> | 8 <sup>(1)</sup>      | D |  |
| Common Stock | 03/18/2015 | S | 9,420  | D | \$ 18.0045 <sup>(3)</sup> | 408,328               | I | Gregory T Went & Marjorie S Went ttees Went Family Living Trust dtd 03/24/11 |
| Common Stock | 03/19/2015 | M | 12,320 | A | \$ 1.875                  | 12,328 <sup>(1)</sup> | D |  |
| Common Stock | 03/19/2015 | S | 2,320  | D | \$ 18                     | 10,008 <sup>(1)</sup> | D |  |
| Common Stock | 03/19/2015 | S | 2,148  | D | \$ 18                     | 406,180               | I | Gregory T Went & Marjorie S Went ttees Went Family Living Trust dtd 03/24/11 |
| Common Stock |            |   |        |   |                           | 6,666                 | I | Gregory T Went Cust - Bridget Went Under CA Uniform Transfers to Minors Act  |
| Common Stock |            |   |        |   |                           | 6,666                 | I | Gregory T Went Cust - Cora Went Under CA Uniform Transfers to Minors         |

Edgar Filing: Adamas Pharmaceuticals Inc - Form 4

|              |        |   |  |
|--------------|--------|---|--|
| Common Stock | 80,000 | I | Act<br>Gregory T Went & Marjorie S Went<br>tees 2012<br>Irr Trust<br>FBO<br>Bridget Elise Went<br>Gregory T Went & Marjorie S Went<br>tees 2012<br>Irr Trust<br>FBO Cora Margaret Went |
| Common Stock | 80,000 | I |  |

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**

SEC 1474  
(9-02)

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned**  
(e.g., puts, calls, warrants, options, convertible securities)

| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. Transaction Code (Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) | 6. Date Exercisable and Expiration Date (Month/Day/Year) | 7. Title and Amount of Underlying Securities (Instr. 3 and 4) | 8. Amount or Number of Shares |
|--|--|--------------------------------------|--|--------------------------------|---|--|---|-------------------------------|
| Stock Option (Right to Buy)                | \$ 1.875   | 03/17/2015                           |  | M                              | 1,900   | <sup>(4)</sup> 09/12/2016                                | Common Stock  | 1,900                         |
| Stock Option (Right to Buy)                | \$ 1.875   | 03/18/2015                           |  | M                              | 4,600   | <sup>(4)</sup> 09/12/2016                                | Common Stock  | 4,600                         |

|                                      |          |            |   |        |            |            |                 |        |
|--------------------------------------|----------|------------|---|--------|------------|------------|-----------------|--------|
| Stock<br>Option<br>(Right to<br>Buy) | \$ 1.875 | 03/19/2015 | M | 12,320 | <u>(4)</u> | 09/12/2016 | Common<br>Stock | 12,320 |
|--------------------------------------|----------|------------|---|--------|------------|------------|-----------------|--------|

## Reporting Owners

| Reporting Owner Name / Address   | Relationships |           |                         |       |
|--|---------------|-----------|-------------------------|-------|
|  | Director      | 10% Owner | Officer                 | Other |
| Went Gregory T<br>C/O ADAMAS PHARMACEUTICALS, INC.<br>1900 POWELL ST., SUITE 750<br>EMERYVILLE, CA 94608 | X             | X         | Chief Executive Officer |       |

## Signatures

/s/Grace Shin, as  
Attorney-in-Fact

03/19/2015

\_\_Signature of Reporting Person

Date

## Explanation of Responses:

- \* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.
- (2) The price reported in Column 4 is an average price. These shares were sold in multiple transactions at prices ranging from \$18.00 to 18.02, inclusive.
- (3) The price reported in Column 4 is an average price. These shares were sold in multiple transactions at prices ranging from \$18.00 to 18.09, inclusive.
- (4) This option is fully vested and exercisable.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.